{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:16:17Z","timestamp":1793945777024,"version":"4.8.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["ID 24315"],"award-info":[{"award-number":["ID 24315"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["ID 24451"],"award-info":[{"award-number":["ID 24451"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente"],"award-info":[{"award-number":["Ricerca Corrente"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bcl-xL plays an important role in tumors from different origins, including melanoma, and for this reason it has been widely targeted with small-molecule BH3 mimetics, which unfortunately show several adverse effects. To overcome this limitation, selective Bcl-xL proteolysis-targeting chimera degraders have been developed. Among these, DT2216, a candidate in phase I\/II clinical trials, has demonstrated antitumoral activity in preclinical cancer models from different origins, not including melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      By using several established and patient-derived BRAF\n                      <jats:italic>wild type<\/jats:italic>\n                      and mutated melanoma cells, we performed western blot analysis and MTT assay to study DT2216 effect on Bcl-xL protein levels and cell viability, respectively. Combination studies were performed on BRAF mutated melanoma cells treated with DT2216 and Dabrafenib\/Trametinib or on\n                      <jats:italic>wild type<\/jats:italic>\n                      melanoma cells treated with DT2216 and Trametinib or S63845. Combination index was calculated to study drug interactions. Apoptotic induction was studied through western blot (PARP-1 cleavage), cytofluorimetric (subG1 peak in the cell cycle) and live-cell fluorescent imaging of activated caspases 3\/7 analyses. Group differences were analysed with a two-sided paired or unpaired Student\u2019s t-test. To investigate the effect of the combination treatment in vivo, A375luc melanoma cells were inoculated in xenograft mice, then treated with Dabrafenib\/Trametinib or DT2216, alone or in combination, for three weeks. Differences between groups, were analysed with Mann-Whitney test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DT2216 induced the specific and long-lasting degradation of Bcl-xL protein, and reduced cell viability, in a concentration-dependent manner. Of note, a positive correlation between Bcl-xL degradation and sensitivity to DT2216 was observed, being cells with higher degradation the most sensitive to DT2216. In combination studies, DT2216 was able to enhance the activity of target therapy regardless BRAF mutational status. Moreover, the Mcl-1 specific inhibitor, S63845, potentiated the efficacy of DT2216 in melanoma cells in which DT2216 determined an increase of Mcl-1 protein. Interestingly, DT2216 also increased the activity of target therapy in melanoma cells resistant to Dabrafenib and Trametinib. Finally, experiments in a xenograft mouse melanoma model highlighted DT2216 potentiating effect of target therapy, not only inducing a significant reduction of tumor growth, but also showing a longer disease control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings provide new insights for combination therapy including Bcl-xL degradation for melanoma treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03635-w","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:37:04Z","timestamp":1767843424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models"],"prefix":"10.1186","volume":"45","author":[{"given":"Elisabetta","family":"Valentini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Di Martile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"D\u2019Aguanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Brignone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Maria","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marica","family":"Di Caprio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Melucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Botti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Pelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Ortolano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Fattore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Ciliberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dante","family":"Rotili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Del Bufalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"3635_CR1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00012","author":"LB Kennedy","year":"2022","unstructured":"Kennedy LB, Salama AKS. A marathon not a sprint: improving outcomes for patients with metastatic melanoma in 2022 and beyond. JCO Oncol Pract. 2022. https:\/\/doi.org\/10.1200\/OP.22.00012.","journal-title":"JCO Oncol Pract"},{"key":"3635_CR2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"key":"3635_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081571","author":"A Fateeva","year":"2024","unstructured":"Fateeva A, Eddy K, Chen S. Current state of melanoma therapy and next steps: battling therapeutic resistance. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16081571.","journal-title":"Cancers (Basel)"},{"key":"3635_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052777","author":"AM Luciano","year":"2021","unstructured":"Luciano AM, Perez-Oliva AB, Mulero V, Del Bufalo D. Bcl-xL: A focus on melanoma pathobiology. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22052777.","journal-title":"Int J Mol Sci"},{"key":"3635_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-022-01780-7","author":"D Kaloni","year":"2023","unstructured":"Kaloni D, Diepstraten ST, Strasser A, Kelly GL. BCL-2 protein family: attractive targets for cancer therapy. Apoptosis. 2023. https:\/\/doi.org\/10.1007\/s10495-022-01780-7.","journal-title":"Apoptosis"},{"key":"3635_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.233","author":"A Scherr","year":"2016","unstructured":"Scherr A, Gdynia G, Salou M, Radhakrishnan P, Duglova K, Heller A, et al. Bcl-xL is an oncogenic driver in colorectal cancer. Cell Death Dis. 2016. https:\/\/doi.org\/10.1038\/cddis.2016.233.","journal-title":"Cell Death Dis"},{"key":"3635_CR7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-0431","author":"Y Sela","year":"2022","unstructured":"Sela Y, Li J, Maheswaran S, Norgard R, Yuan S, Hubbi M, et al. Bcl-xL enforces a Slow-Cycling state necessary for survival in the Nutrient-Deprived microenvironment of pancreatic cancer. Cancer Res. 2022. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0431.","journal-title":"Cancer Res"},{"key":"3635_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2017.02.001","author":"K Ikezawa","year":"2017","unstructured":"Ikezawa K, Hikita H, Shigekawa M, Iwahashi K, Eguchi H, Sakamori R, et al. Increased Bcl-xL expression in pancreatic neoplasia promotes carcinogenesis by inhibiting senescence and apoptosis. Cell Mol Gastroenterol Hepatol. 2017. https:\/\/doi.org\/10.1016\/j.jcmgh.2017.02.001.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"3635_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071659","author":"C Alcon","year":"2021","unstructured":"Alcon C, Gomez Tejeda Zanudo J, Albert R, Wagle N, Scaltriti M, Letai A, et al. ER\u2009+\u2009Breast cancer strongly depends on MCL-1 and BCL-xL Anti-Apoptotic proteins. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10071659.","journal-title":"Cells"},{"key":"3635_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-023-00013-x","author":"A Bodac","year":"2024","unstructured":"Bodac A, Mayet A, Rana S, Pascual J, Bowler AD, Roh V, et al. Bcl-xL targeting eliminates ageing tumor-promoting neutrophils and inhibits lung tumor growth. EMBO Mol Med. 2024. https:\/\/doi.org\/10.1038\/s44321-023-00013-x.","journal-title":"EMBO Mol Med"},{"key":"3635_CR11","doi-asserted-by":"publisher","DOI":"10.7150\/thno.60503","author":"O Castellanet","year":"2021","unstructured":"Castellanet O, Ahmad F, Vinik Y, Mills GB, Habermann B, Borg J, et al. BCL-XL blockage in TNBC models confers vulnerability to Inhibition of specific cell cycle regulators. Theranostics. 2021. https:\/\/doi.org\/10.7150\/thno.60503.","journal-title":"Theranostics"},{"key":"3635_CR12","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-07-0088","author":"S Giorgini","year":"2007","unstructured":"Giorgini S, Trisciuoglio D, Gabellini C, Desideri M, Castellini L, Colarossi C, et al. Modulation of bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression. Mol Cancer Res. 2007. https:\/\/doi.org\/10.1158\/1541-7786.MCR-07-0088.","journal-title":"Mol Cancer Res"},{"key":"3635_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31075","author":"C Gabellini","year":"2018","unstructured":"Gabellini C, Gomez-Abenza E, Ibanez-Molero S, Tupone MG, Perez-Oliva AB, de Oliveira S, et al. Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model. Int J Cancer. 2018. https:\/\/doi.org\/10.1002\/ijc.31075.","journal-title":"Int J Cancer"},{"key":"3635_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02735-9","author":"AM Luciano","year":"2023","unstructured":"Luciano AM, Di Martile M, Perez-Oliva AB, Di Caprio M, Foddai ML, Buglioni S, et al. Exploring association of melanoma-specific Bcl-xL with tumor immune microenvironment. J Exp Clin Cancer Res. 2023. https:\/\/doi.org\/10.1186\/s13046-023-02735-9.","journal-title":"J Exp Clin Cancer Res"},{"key":"3635_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-024-01417-z","author":"C Alcon","year":"2024","unstructured":"Alcon C, Kovatcheva M, Morales-Sanchez P, Lopez-Polo V, Torres T, Puig S, et al. HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells. Cell Death Differ. 2024. https:\/\/doi.org\/10.1038\/s41418-024-01417-z.","journal-title":"Cell Death Differ"},{"key":"3635_CR16","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.9b00568","author":"L Wang","year":"2020","unstructured":"Wang L, Doherty GA, Judd AS, Tao Z, Hansen TM, Frey RR, et al. Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X(L) inhibitor. ACS Med Chem Lett. 2020. https:\/\/doi.org\/10.1021\/acsmedchemlett.9b00568.","journal-title":"ACS Med Chem Lett"},{"key":"3635_CR17","doi-asserted-by":"publisher","DOI":"10.1021\/ml5001867","author":"Z Tao","year":"2014","unstructured":"Tao Z, Hasvold L, Wang L, Wang X, Petros AM, Park CH, et al. Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACS Med Chem Lett. 2014. https:\/\/doi.org\/10.1021\/ml5001867.","journal-title":"ACS Med Chem Lett"},{"key":"3635_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1246","author":"G Lessene","year":"2013","unstructured":"Lessene G, Czabotar PE, Sleebs BE, Zobel K, Lowes KN, Adams JM, et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol. 2013. https:\/\/doi.org\/10.1038\/nchembio.1246.","journal-title":"Nat Chem Biol"},{"key":"3635_CR19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5836","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5836.","journal-title":"Cancer Res"},{"key":"3635_CR20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347849","author":"SM Schoenwaelder","year":"2011","unstructured":"Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011. https:\/\/doi.org\/10.1182\/blood-2011-04-347849.","journal-title":"Blood"},{"key":"3635_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27210-x","author":"D Lv","year":"2021","unstructured":"Lv D, Pal P, Liu X, Jia Y, Thummuri D, Zhang P, et al. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nat Commun. 2021. https:\/\/doi.org\/10.1038\/s41467-021-27210-x.","journal-title":"Nat Commun"},{"key":"3635_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21573-x","author":"R Kolb","year":"2021","unstructured":"Kolb R, De U, Khan S, Luo Y, Kim M, Yu H, et al. Proteolysis-targeting chimera against BCL-X(L) destroys tumor-infiltrating regulatory T cells. Nat Commun. 2021. https:\/\/doi.org\/10.1038\/s41467-021-21573-x.","journal-title":"Nat Commun"},{"key":"3635_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104376","author":"M Cornu","year":"2025","unstructured":"Cornu M, Lemaitre T, Kieffer C, Voisin-Chiret AS. PROTAC 2.0: expanding the frontiers of targeted protein degradation. Drug Discov Today. 2025. https:\/\/doi.org\/10.1016\/j.drudis.2025.104376.","journal-title":"Drug Discov Today"},{"key":"3635_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-01173-2","author":"K Garber","year":"2022","unstructured":"Garber K. The PROTAC gold rush. Nat Biotechnol. 2022. https:\/\/doi.org\/10.1038\/s41587-021-01173-2.","journal-title":"Nat Biotechnol"},{"key":"3635_CR25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008899","author":"V Gress","year":"2024","unstructured":"Gress V, Roussy M, Boulianne L, Bilodeau M, Cardin S, El-Hachem N, et al. CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL Inhibition by navitoclax and DT2216. Blood Adv. 2024. https:\/\/doi.org\/10.1182\/bloodadvances.2022008899.","journal-title":"Blood Adv"},{"key":"3635_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01296-8","author":"S Khan","year":"2023","unstructured":"Khan S, Kellish P, Connis N, Thummuri D, Wiegand J, Zhang P, et al. Co-targeting BCL-X(L) and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. Cell Death Discov. 2023. https:\/\/doi.org\/10.1038\/s41420-022-01296-8.","journal-title":"Cell Death Discov"},{"key":"3635_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.161820","author":"B Shebl","year":"2022","unstructured":"Shebl B, Ng D, Lalazar G, Rosemore C, Finkelstein TM, Migler RD, et al. Targeting BCL-XL in fibrolamellar hepatocellular carcinoma. JCI Insight. 2022. https:\/\/doi.org\/10.1172\/jci.insight.161820.","journal-title":"JCI Insight"},{"key":"3635_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06478-z","author":"LJ Jenkins","year":"2024","unstructured":"Jenkins LJ, Luk IY, Chionh F, Tan T, Needham K, Ayton J, et al. BCL-X(L) inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF(V600E) colorectal cancer. Cell Death Dis. 2024. https:\/\/doi.org\/10.1038\/s41419-024-06478-z.","journal-title":"Cell Death Dis"},{"key":"3635_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0668-z","author":"S Khan","year":"2019","unstructured":"Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019. https:\/\/doi.org\/10.1038\/s41591-019-0668-z.","journal-title":"Nat Med"},{"key":"3635_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112186","author":"X Zhang","year":"2020","unstructured":"Zhang X, Thummuri D, Liu X, Hu W, Zhang P, Khan S, et al. Discovery of PROTAC BCL-X(L) degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112186.","journal-title":"Eur J Med Chem"},{"key":"3635_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01753-8","author":"D Mahadevan","year":"2025","unstructured":"Mahadevan D, Barve M, Mahalingam D, Parekh J, Kurman M, Strauss J, et al. First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed\/refractory solid malignancies. J Hematol Oncol. 2025. https:\/\/doi.org\/10.1186\/s13045-025-01753-8.","journal-title":"J Hematol Oncol"},{"key":"3635_CR32","doi-asserted-by":"publisher","DOI":"10.7150\/thno.64233","author":"E Valentini","year":"2022","unstructured":"Valentini E, D\u2019Aguanno S, Di Martile M, Montesano C, Ferraresi V, Patsilinakos A, et al. Targeting the anti-apoptotic Bcl-2 family proteins: machine learning virtual screening and biological evaluation of new small molecules. Theranostics. 2022. https:\/\/doi.org\/10.7150\/thno.64233.","journal-title":"Theranostics"},{"key":"3635_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000489","author":"M Di Martile","year":"2020","unstructured":"Di Martile M, Farini V, Consonni FM, Trisciuoglio D, Desideri M, Valentini E, et al. Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2019-000489.","journal-title":"J Immunother Cancer"},{"key":"3635_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05963-1","author":"E Valentini","year":"2023","unstructured":"Valentini E, Di Martile M, Brignone M, Di Caprio M, Manni I, Chiappa M, et al. Bcl-2 family inhibitors sensitize human cancer models to therapy. Cell Death Dis. 2023. https:\/\/doi.org\/10.1038\/s41419-023-05963-1.","journal-title":"Cell Death Dis"},{"key":"3635_CR35","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00919","author":"Z Wang","year":"2019","unstructured":"Wang Z, He N, Guo Z, Niu C, Song T, Guo Y, et al. Proteolysis targeting chimeras for the selective degradation of Mcl-1\/Bcl-2 derived from nonselective target binding ligands. J Med Chem. 2019. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00919.","journal-title":"J Med Chem"},{"key":"3635_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1568-3","author":"EF Lee","year":"2019","unstructured":"Lee EF, Harris TJ, Tran S, Evangelista M, Arulananda S, John T, et al. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis. 2019. https:\/\/doi.org\/10.1038\/s41419-019-1568-3.","journal-title":"Cell Death Dis"},{"key":"3635_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11060463","author":"M Lasica","year":"2021","unstructured":"Lasica M, Anderson MA. Review of venetoclax in CLL, AML and multiple myeloma. J Pers Med. 2021. https:\/\/doi.org\/10.3390\/jpm11060463.","journal-title":"J Pers Med"},{"key":"3635_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/nature19830","author":"A Kotschy","year":"2016","unstructured":"Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016. https:\/\/doi.org\/10.1038\/nature19830.","journal-title":"Nature"},{"key":"3635_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020214","author":"N Natarelli","year":"2024","unstructured":"Natarelli N, Aleman SJ, Mark IM, Tran JT, Kwak S, Botto E, et al. A review of current and pipeline drugs for treatment of melanoma. Pharmaceuticals (Basel). 2024. https:\/\/doi.org\/10.3390\/ph17020214.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3635_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.01.027","author":"D Trisciuoglio","year":"2021","unstructured":"Trisciuoglio D, Del Bufalo D. New insights into the roles of antiapoptotic members of the Bcl-2 family in melanoma progression and therapy. Drug Discov Today. 2021. https:\/\/doi.org\/10.1016\/j.drudis.2021.01.027.","journal-title":"Drug Discov Today"},{"key":"3635_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-020-01601-9","author":"P Ramesh","year":"2020","unstructured":"Ramesh P, Medema JP. BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy. Apoptosis. 2020. https:\/\/doi.org\/10.1007\/s10495-020-01601-9.","journal-title":"Apoptosis"},{"key":"3635_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020279","author":"A Kawiak","year":"2022","unstructured":"Kawiak A, Kostecka A. Regulation of Bcl-2 family proteins in Estrogen Receptor-Positive breast cancer and their implications in endocrine therapy. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14020279.","journal-title":"Cancers (Basel)"},{"key":"3635_CR43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7898","author":"AW Roberts","year":"2012","unstructured":"Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012. https:\/\/doi.org\/10.1200\/JCO.2011.34.7898.","journal-title":"J Clin Oncol"},{"key":"3635_CR44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3090","author":"CM Rudin","year":"2012","unstructured":"Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3090.","journal-title":"Clin Cancer Res"},{"key":"3635_CR45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.6208","author":"L Gandhi","year":"2011","unstructured":"Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, et al. Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011. https:\/\/doi.org\/10.1200\/JCO.2010.31.6208.","journal-title":"J Clin Oncol"},{"key":"3635_CR46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3135","author":"RB Corcoran","year":"2024","unstructured":"Corcoran RB, Do KT, Kim JE, Cleary JM, Parikh AR, Yeku OO, et al. Phase I\/II study of combined BCL-xL and MEK Inhibition with navitoclax and Trametinib in KRAS or NRAS mutant advanced solid tumors. Clin Cancer Res. 2024. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3135.","journal-title":"Clin Cancer Res"},{"key":"3635_CR47","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00146","author":"A Dolle","year":"2021","unstructured":"Dolle A, Adhikari B, Kramer A, Weckesser J, Berner N, Berger L, et al. Design, Synthesis, and evaluation of WD-Repeat-Containing protein 5 (WDR5) degraders. J Med Chem. 2021. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00146.","journal-title":"J Med Chem"},{"key":"3635_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2023.06.002","author":"MP Schwalm","year":"2023","unstructured":"Schwalm MP, Kramer A, Dolle A, Weckesser J, Yu X, Jin J, et al. Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization. Cell Chem Biol. 2023. https:\/\/doi.org\/10.1016\/j.chembiol.2023.06.002.","journal-title":"Cell Chem Biol"},{"key":"3635_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcis.2024.08.185","author":"W Zhang","year":"2025","unstructured":"Zhang W, Jin Y, Wang J, Gu M, Wang Y, Zhang X, et al. Co-delivery of PROTAC and SiRNA via novel liposomes for the treatment of malignant tumors. J Colloid Interface Sci. 2025. https:\/\/doi.org\/10.1016\/j.jcis.2024.08.185.","journal-title":"J Colloid Interface Sci"},{"key":"3635_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101070","author":"S Han","year":"2025","unstructured":"Han S, Tushoski-Aleman GW, Zhang P, Zheng G, Zhou D, Huo Z, et al. A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR. Neoplasia. 2025. https:\/\/doi.org\/10.1016\/j.neo.2024.101070.","journal-title":"Neoplasia"},{"key":"3635_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.06.019","author":"Y Lee","year":"2018","unstructured":"Lee Y, Wang L, Huang C, Shi Y, Chang L. ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells. Cancer Lett. 2018. https:\/\/doi.org\/10.1016\/j.canlet.2018.06.019.","journal-title":"Cancer Lett"},{"key":"3635_CR52","doi-asserted-by":"publisher","DOI":"10.1515\/bmc-2016-0015","author":"J Hatok","year":"2016","unstructured":"Hatok J, Racay P. Bcl-2 family proteins: master regulators of cell survival. Biomol Concepts. 2016. https:\/\/doi.org\/10.1515\/bmc-2016-0015.","journal-title":"Biomol Concepts"},{"key":"3635_CR53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2088","author":"SI Tantawy","year":"2023","unstructured":"Tantawy SI, Sarkar A, Hubner S, Tan Z, Wierda WG, Eldeib A, et al. Mechanisms of MCL-1 protein stability induced by MCL-1 antagonists in B-Cell malignancies. Clin Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2088.","journal-title":"Clin Cancer Res"},{"key":"3635_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116542","author":"X Zhang","year":"2024","unstructured":"Zhang X, Tao Y, Xu Z, Jiang B, Yang X, Huang T, et al. Sorafenib and SIAIS361034, a novel PROTAC degrader of BCL-x(L), display synergistic antitumor effects on hepatocellular carcinoma with minimal hepatotoxicity. Biochem Pharmacol. 2024. https:\/\/doi.org\/10.1016\/j.bcp.2024.116542.","journal-title":"Biochem Pharmacol"},{"key":"3635_CR55","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0474","author":"D Thummuri","year":"2022","unstructured":"Thummuri D, Khan S, Underwood PW, Zhang P, Wiegand J, Zhang X, et al. Overcoming gemcitabine resistance in pancreatic cancer using the BCL-X(L)-Specific degrader DT2216. Mol Cancer Ther. 2022. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0474.","journal-title":"Mol Cancer Ther"},{"key":"3635_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00928-9","author":"Y He","year":"2020","unstructured":"He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, et al. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020. https:\/\/doi.org\/10.1186\/s13045-020-00928-9.","journal-title":"J Hematol Oncol"},{"key":"3635_CR57","doi-asserted-by":"publisher","DOI":"10.1101\/gad.215871.113","author":"RL Thomas","year":"2013","unstructured":"Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 2013. https:\/\/doi.org\/10.1101\/gad.215871.113.","journal-title":"Genes Dev"},{"key":"3635_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07481-8","author":"L Zhang","year":"2025","unstructured":"Zhang L, Wei Y, Luo M, Ren S, Zhan X, Wang C, et al. Both direct and indirect suppression of MCL1 synergizes with BCLXL Inhibition in preclinical models of gastric cancer. Cell Death Dis. 2025. https:\/\/doi.org\/10.1038\/s41419-025-07481-8.","journal-title":"Cell Death Dis"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03635-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03635-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03635-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T11:50:29Z","timestamp":1770205829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03635-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3635"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03635-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Isolation of patient-derived melanoma cells was approved by Ethical committee of the IRCCS Regina Elena National Cancer Institute, Rome, Italy (# 1441\/20).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}